Molecular Pharmacology Stock Market Value
| MLPH Stock | USD 0.0003 0.01 96.91% |
| Symbol | Molecular |
Molecular Pharmacology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Pharmacology's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Pharmacology.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Molecular Pharmacology on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Pharmacology or generate 0.0% return on investment in Molecular Pharmacology over 90 days. Molecular Pharmacology is related to or competes with Unidoc Health, and Devonian Health. Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation managemen... More
Molecular Pharmacology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Pharmacology's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Pharmacology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1438 | |||
| Maximum Drawdown | 1840.0 | |||
| Potential Upside | 20.0 |
Molecular Pharmacology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Pharmacology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Pharmacology's standard deviation. In reality, there are many statistical measures that can use Molecular Pharmacology historical prices to predict the future Molecular Pharmacology's volatility.| Risk Adjusted Performance | 0.1263 | |||
| Jensen Alpha | 29.48 | |||
| Total Risk Alpha | 16.53 | |||
| Treynor Ratio | 0.4405 |
Molecular Pharmacology February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1263 | |||
| Market Risk Adjusted Performance | 0.4505 | |||
| Mean Deviation | 70.86 | |||
| Coefficient Of Variation | 693.93 | |||
| Standard Deviation | 236.89 | |||
| Variance | 56118.68 | |||
| Information Ratio | 0.1438 | |||
| Jensen Alpha | 29.48 | |||
| Total Risk Alpha | 16.53 | |||
| Treynor Ratio | 0.4405 | |||
| Maximum Drawdown | 1840.0 | |||
| Potential Upside | 20.0 | |||
| Skewness | 7.2 | |||
| Kurtosis | 54.27 |
Molecular Pharmacology Backtested Returns
Molecular Pharmacology is out of control given 3 months investment horizon. Molecular Pharmacology has Sharpe Ratio of 0.15, which conveys that the firm had a 0.15 % return per unit of risk over the last 3 months. We were able to interpolate data for nineteen different technical indicators, which can help you to evaluate if expected returns of 22.43% are justified by taking the suggested risk. Use Molecular Pharmacology Risk Adjusted Performance of 0.1263, mean deviation of 70.86, and Standard Deviation of 236.89 to evaluate company specific risk that cannot be diversified away. Molecular Pharmacology holds a performance score of 12 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 77.48, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Molecular Pharmacology will likely underperform. Use Molecular Pharmacology variance, skewness, as well as the relationship between the Skewness and price action indicator , to analyze future returns on Molecular Pharmacology.
Auto-correlation | 0.00 |
No correlation between past and present
Molecular Pharmacology has no correlation between past and present. Overlapping area represents the amount of predictability between Molecular Pharmacology time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Pharmacology price movement. The serial correlation of 0.0 indicates that just 0.0% of current Molecular Pharmacology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.63 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.